Introduction of HAART Partially Responsible for Resurgence in Syphilis

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

THURSDAY, April 30, 2026 -- Introduction of the highly active antiretroviral therapy (HAART) drug regimen was partially responsible for the recent resurgence in syphilis in the United States, according to a study published online April 22 in Health Economics.

Noting that the incidence of syphilis increased starting in 2000, recently reaching a 60-year peak, David Beheshti, Ph.D., from the University of Texas at San Antonio, and colleagues suggest that the increase was partly due to introduction of the HAART drug regimen, which transformed HIV from a terminal condition into a manageable chronic disease. To test this empirically, variation in HAART uptake was exploited based on spatial variation in pre‐HAART AIDS prevalence, sex, and time in a triple differences framework.

The researchers found that a one standard deviation increase in the pre-HAART prevalence of AIDS led to a 17.8 percent increase in the rate of syphilis incidence. Between 1996 and 2008, there would have been 81 percent fewer syphilis cases in the absence of HAART.

"With syphilis now at a 60‐year high, these findings offer timely insight into how life‐saving innovations can reshape population behavior and highlight the need for complementary public health strategies," Beheshti said in a statement.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-05-01 02:14

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords